40 results about "Thiosulfonic Acids" patented technology

This invention pertains generally to the field of chemical synthesis and purification, and more specifically to methods of synthesizing and purifying certain 3,7 diamino-phenothiazin-5-ium compounds (referred to herein as “diaminophenothiazinium compounds”) including Methylthioninium Chloride (MTC) (also known as Methylene Blue). In one embodiment, the method comprises the steps of, in order: nitrosylation (NOS); nitrosyl reduction (NR); thiosulfonic acid formation (TSAF); oxidative coupling (OC); Cr(VI) reduction (CR); isolation and purification of zwitterionic intermediate (IAPOZI); ring closure (RC); chloride salt formation (CSF); one of: sulphide treatment (ST); dimethyldithiocarbamate treatment (DT); carbonate treatment (CT); ethylenediaminetetraacetic acid treatment (EDTAT); organic extraction (OE); and recrystallisation (RX). The present invention also pertains to the resulting (high purity) compounds, compositions comprising them (e.g., tablets, capsules), and their use in methods of inactivating pathogens, and methods of medical treatment and diagnosis, etc., for example, for tauopathies, Alzheimer's disease (AD), skin cancer, melanoma, viral diseases, bacterial diseases, or protozoal diseases. Wherein: each of R1 and R9 is independently selected from: —H; C1-4 alkenyl; and halogenated C1-4alkyl; each of R3NA and R3NB is independently selected from: C1-4 alkyl; C2-4alkenyl; and halogenated C4-1 alkyl; each of R7NA and R7NB is independently selected from: C1-4 alkyl; C2-4alkenyl; and halogenated C1-4 alkyl; and X is one or more anionic counter ions to achieve electrical neutrality.

The invention discloses an abalone blood cell anticoagulant protective agent and a preparation method thereof, and relates to an anticoagulant protective agent. The invention provides an abalone blood cell anticoagulant protective agent for maintaining the activity of isolated abalone blood cells within longer time and a preparation method thereof. The abalone blood cell anticoagulant protective agent comprises the following raw materials by mass percentage: 1.95 to 2.08 percent of glucose, 0.78 to 0.8 percent of sodium citrate (2H2O), 0.063 to 0.107 percent of citric acid, 0.37 to 0.57 percent of sodium chloride, 0.21 to 0.24 percent of hydroxyethyl piperazinyl ethyl thiosulfonic acid, and 100 percent of double distilled water, wherein the pH value is between 6.0 and 6.4. The abalone blood cell anticoagulant protective agent is obtained by dissolving the glucose, the sodium citrate (2H2O), the sodium chloride and the hydroxyethyl piperazinyl ethyl thiosulfonic acid into the double distilled water, stirring and dissolving the mixture, using the citric acid to adjust the pH value to be between 6.0 and 6.4, and performing high-temperature sterilization.

The invention discloses a compound containing monofluorochloromethylthiosulfonate represented by formula 1, a preparation method and application thereof. The preparation method of the compound shown in formula 1 includes the following steps: reacting with sodium phenylsulfinate in chlorine gas solution. The compound shown in formula 1 of the present invention can be used as a fluorochloromethylthiolation reagent, and its application yield is high, thereby providing an important methodological research tool for the fields of medicine, pesticides and materials.